메뉴 건너뛰기




Volumn 161, Issue 1, 2009, Pages 21-25

Successful use of weekly pegvisomant administration in patients with acromegaly

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; PEGVISOMANT; SOMATOMEDIN C; DRUG DERIVATIVE; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE;

EID: 67650755038     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0990     Document Type: Article
Times cited : (31)

References (12)
  • 4
    • 85137138074 scopus 로고    scopus 로고
    • Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, BennettWF & Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 20 1171-1177.
    • Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, BennettWF & Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 20 1171-1177.
  • 5
    • 15944375488 scopus 로고    scopus 로고
    • Alternate day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly
    • Jehle S, Reyes CM, Sundeen RE & Freda PU. Alternate day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 1588-1593.
    • (2005) Journal of Clinical Endocrinology and Metabolism , vol.90 , pp. 1588-1593
    • Jehle, S.1    Reyes, C.M.2    Sundeen, R.E.3    Freda, P.U.4
  • 6
    • 18744389775 scopus 로고    scopus 로고
    • Feenstra J, de Herder WW, ten Have SM, van den Beld AV, Feelders RA, Janssen JA & van der Lely AJ. Combined therapy with somatostatin analogs and weekly pegvisomant in active acromegaly. Lancet 2005 365 1644-1646.
    • Feenstra J, de Herder WW, ten Have SM, van den Beld AV, Feelders RA, Janssen JA & van der Lely AJ. Combined therapy with somatostatin analogs and weekly pegvisomant in active acromegaly. Lancet 2005 365 1644-1646.
  • 8
    • 21244495705 scopus 로고    scopus 로고
    • Quality of life (QOL) in patients with acromegaly is severely impaired: Use of a novel measure of QOL: acromegaly quality of life questionnaire
    • Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM & Trainer PJ. Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. Journal of Clinical Endocrinology and Metabolism 2005 90 3337-3341.
    • (2005) Journal of Clinical Endocrinology and Metabolism , vol.90 , pp. 3337-3341
    • Rowles, S.V.1    Prieto, L.2    Badia, X.3    Shalet, S.M.4    Webb, S.M.5    Trainer, P.J.6
  • 9
    • 20244383254 scopus 로고    scopus 로고
    • Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF1) and IGF-binding protein 3 (IGFBP-3)
    • Elmlinger MW, Kühnel W, Weber MM & Ranke MB. Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF1) and IGF-binding protein 3 (IGFBP-3). Clinical Chemistry and Laboratory Medicine 2004 42 654-664.
    • (2004) Clinical Chemistry and Laboratory Medicine , vol.42 , pp. 654-664
    • Elmlinger, M.W.1    Kühnel, W.2    Weber, M.M.3    Ranke, M.B.4
  • 10
    • 77949270852 scopus 로고    scopus 로고
    • Endogenous estradiol may influence IGF1 levels in acromegalic women treated with pegvisomant
    • In Press,DOI: 10.1007/s11102-008-0131-5
    • Roemmler J, Bidlingmaier M & Schopol J. Endogenous estradiol may influence IGF1 levels in acromegalic women treated with pegvisomant. Pituitary, 2008. In Press,DOI: 10.1007/s11102-008-0131-5.
    • (2008) Pituitary
    • Roemmler, J.1    Bidlingmaier, M.2    Schopol, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.